H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $11.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).

The analyst commented: "Eupraxia reported 36-week data from Cohort 9, the highest-dose cohort in the Phase 1b/2a RESOLVE study, further extending what is now the clearest signal in the dataset: EP-104GI can deliver durable, clinically meaningful responses following a single administration. At nine months, 66% of patients remained in clinical remission (2/3), with responses achieved as early as week 8 and maintained through week 36, alongside continued improvements in tissue health (EoEHSS Stage -90%, Grade -88%) and a 72% reduction in peak eosinophil count. In our view, these data reinforce the emerging dose-response relationship and position the high-dose, broad-coverage regimen as the leading approach as the program advances toward randomized evaluation. Reiterate Buy rating and $11 PT."

For an analyst ratings summary and ratings history on Eupraxia Pharmaceuticals click here. For more ratings news on Eupraxia Pharmaceuticals click here.

Shares of Eupraxia Pharmaceuticals closed at $7.02 yesterday.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• Howard Hughes Holdings to join S&P SmallCap 600 on Oct. 28
• Vital Farms pilots free-range eggs at Target stores under $5